Rui Tang

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial

Daniel V.T. Catenacci, Niall C. Tebbutt, André M. Murad et al. · The Lancet Oncology · 2017 · 343 citations · Full text

Medicine, Oncology, Pharmacology +15

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study

Timothy Iveson, Ross C. Donehower, S. Tjulandin et al. · The Lancet Oncology · 2014 · 261 citations

Medicine, Oncology, Pharmacology +15

A single-cell transcriptomic landscape of the lungs of patients with COVID-19

Si Wang, Xiaohong Yao, Shuai Ma et al. · Nature Cell Biology · 2021 · 212 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +12

Mouse miRNA-709 directly regulates miRNA-15a/16-1 biogenesis at the posttranscriptional level in the nucleus: evidence for a microRNA hierarchy system

Rui Tang, Limin Li, Dihan Zhu et al. · Cell Research · 2011 · 196 citations

Life Sciences, Genetics, Molecular Biology +10

Autopsy of COVID-19 patients in China

Xiu‐Wu Bian, Xiaohong Yao, Yi‐Fang Ping et al. · National Science Review · 2020 · 153 citations · Full text

Medicine, Infectious Diseases, Pathology +12